Silent Artery Plaque Found in 1 in 13 Adults Under 30 in Landmark Heart Study
A 16,000-person study found atherosclerosis in 57% of healthy adults — including surprisingly young people in their 20s.
Summary
A massive international study called REACT scanned over 16,000 apparently healthy adults for signs of artery disease and found arterial plaque in more than half of them. Strikingly, about 1 in 13 people aged 18 to 29 already had detectable plaques — years or decades before any symptoms would typically appear. Led by researchers in Denmark and Spain and published in the New England Journal of Medicine, the study argues for a shift away from estimating cardiovascular risk using traditional factors like cholesterol and blood pressure, toward directly imaging arteries to catch hidden disease early. The findings suggest atherosclerosis begins far earlier in life than previously understood, opening a window for earlier, more targeted prevention.
Detailed Summary
Atherosclerosis — the gradual buildup of plaque inside arteries that underlies most heart attacks and strokes — has long been thought of as a disease of middle age and beyond. A sweeping new study challenges that assumption, revealing that silent arterial plaque is far more common in young adults than previously recognized.
The REACT study, one of the largest cardiovascular imaging efforts ever conducted, enrolled more than 16,000 apparently healthy adults with no prior cardiovascular diagnosis. Using direct arterial imaging across three major vascular territories, researchers detected atherosclerotic plaques in 57.1% of participants overall. More striking still, roughly 1 in 13 adults between the ages of 18 and 29 already showed signs of plaque accumulation — suggesting the disease can take root before a person reaches their thirties.
The study was led by Professor Henning Bundgaard of Rigshospitalet in Copenhagen and Dr. Borja Ibáñez of CNIC in Spain. Funded by the Novo Nordisk Foundation with up to EUR 23 million for its first phase, REACT is designed to transform cardiovascular prevention through a precision medicine lens. The core idea is straightforward but potentially paradigm-shifting: rather than relying on indirect risk estimates from cholesterol, blood pressure, and smoking status, clinicians could directly visualize disease before symptoms emerge and tailor interventions accordingly.
The findings were presented at ESC Congress 2026 and simultaneously published in the New England Journal of Medicine, lending them significant scientific weight. Cardiovascular disease kills nearly 20 million people annually worldwide, with atherosclerosis responsible for the majority of those deaths. Early detection could allow preventive therapies — including lifestyle changes, statins, or emerging anti-inflammatory drugs — to be deployed years earlier.
Important caveats remain. Detecting plaque does not mean a person will inevitably develop symptomatic disease. Long-term follow-up data are needed to confirm whether early imaging-guided intervention actually reduces events. Nonetheless, the REACT findings reframe cardiovascular prevention as a lifelong endeavor starting well before midlife.
Key Findings
- 57% of over 16,000 apparently healthy adults had detectable arterial plaque on direct imaging.
- 1 in 13 adults aged 18–29 already showed signs of atherosclerosis, decades before typical symptom onset.
- Direct arterial imaging detected disease that traditional risk-factor scoring would have missed entirely.
- REACT proposes shifting prevention from risk estimation to actual disease detection through imaging.
- Atherosclerosis begins accumulating silently far earlier in life than current clinical guidelines assume.
Methodology
This is a news report summarizing findings from the REACT study, a large international observational cohort of 16,000-plus adults. Results were published in the New England Journal of Medicine and presented at ESC Congress 2026, indicating high-tier peer review. The study used direct vascular imaging across three arterial territories, though the full methodology requires review of the primary publication.
Study Limitations
The article is a news summary and does not provide full methodological detail; the primary NEJM publication should be consulted for inclusion criteria, imaging protocols, and statistical analyses. Presence of plaque does not establish that participants will develop symptomatic disease, and long-term outcome data from REACT are not yet available. Generalizability across diverse ethnic and geographic populations should be confirmed in the full paper.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: